中国早期乳腺癌卵巢功能抑制临床应用专家共识（2021年版）

中国抗癌协会乳腺癌专业委员会

doi:10.19401/j.cnki.1007-3639.2022.02.010

您当前的位置：

首页 >

文章列表页 >

中国早期乳腺癌卵巢功能抑制临床应用专家共识（2021年版）

指南与共识 | 更新时间：2025-12-31

- 中国早期乳腺癌卵巢功能抑制临床应用专家共识（2021年版）
- Expert consensus on clinical applications of ovarian function suppression for Chinese women with early breast cancer 2021 CACA-CBCS
- 中国癌症杂志 2022年32卷第2期页码：177-190
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2022.02.010
  中图分类号： R737.9
- 收稿：2021-11-15，
  
  纸质出版：2022-02-28
- 稿件说明：
移动端阅览
中国抗癌协会乳腺癌专业委员会. 中国早期乳腺癌卵巢功能抑制临床应用专家共识（2021年版）[J]. 中国癌症杂志, 2022,32(2):177-190.

Committee of Breast Cancer Society Chinese Anti-Cancer Association,. Expert consensus on clinical applications of ovarian function suppression for Chinese women with early breast cancer 2021 CACA-CBCS[J]. China Oncology, 2022, 32(2): 177-190.
中国抗癌协会乳腺癌专业委员会. 中国早期乳腺癌卵巢功能抑制临床应用专家共识（2021年版）[J]. 中国癌症杂志, 2022,32(2):177-190. DOI： 10.19401/j.cnki.1007-3639.2022.02.010.

Committee of Breast Cancer Society Chinese Anti-Cancer Association,. Expert consensus on clinical applications of ovarian function suppression for Chinese women with early breast cancer 2021 CACA-CBCS[J]. China Oncology, 2022, 32(2): 177-190. DOI： 10.19401/j.cnki.1007-3639.2022.02.010.

摘要

卵巢功能抑制（ovarian function suppression

OFS）已经应用于乳腺癌治疗数十年

早期辅助治疗研究证实

单独进行OFS能够降低50岁以下乳腺癌患者的复发风险

改善生存情况。鉴于新的循证医学数据不断累积

中国抗癌协会乳腺癌专业委员会遂召集国内乳腺癌专家

在《中国早期乳腺癌卵巢功能抑制临床应用专家共识（2018年版）》的基础上共同商讨制订了《中国早期乳腺癌卵巢功能抑制临床应用专家共识（2021年版）》。2021年版共识建议

将药物去势[促性腺激素释放激素激动剂（gonadotropin releasing hormone agonist

GnRHa）]作为绝经前激素受体阳性的早期乳腺癌OFS的首选。中高危绝经前激素受体阳性乳腺癌患者推荐接受OFS的内分泌治疗;低危患者推荐选择性雌激素受体调节剂（selective estrogen receptor modulators

SERM）单药治疗;使用芳香化酶抑制剂（aromatase inhibitor

AI）代替SERM治疗的绝经前患者

需要同时接受OFS治疗。关于OFS联合方案

对绝经前激素受体阳性早期乳腺癌的中危和高危患者

或亚群处理效果模式图（subpopulation treatment effect pattern plot

STEPP）分析的较高风险患者推荐OFS联合AI治疗

OFS联合SERM治疗也是合理的选择。对存在SERM禁忌证的任何风险级别患者

推荐OFS联合AI治疗。关于OFS的使用时机

建议根据激素受体阳性乳腺癌患者化疗前的卵巢功能状态

决定辅助内分泌治疗方案。如果考虑卵巢保护

推荐GnRHa同步化疗

不影响患者的生存获益;如果不考虑卵巢保护

推荐GnRHa可以在化疗结束后直接序贯使用。已接受化疗的患者不推荐确认卵巢功能状态后再使用GnRHa。GnRHa辅助内分泌治疗的标准疗程应为5年。完成5年联合OFS的内分泌治疗后

如未绝经且耐受性良好

推荐继续5年联合OFS的内分泌治疗或5年SERM治疗。低危选择OFS替代化疗的患者

可考虑OFS联合内分泌治疗时长为2年。推荐与患者充分沟通可能出现的不良事件

选用合适的药物去势治疗方案。合理的安全管理能够有效地缓解不良反应

增加患者治疗的依从性。对于接受药物去势的患者

不常规推荐在药物去势治疗过程中监测雌激素水平并根据检测报告来决定是否继续药物去势。但在药物去势后

怀疑不完全的卵巢功能抑制时[包括改变用法如注射人员缺乏相关经验、更换剂型或出现某些可能提示卵巢功能恢复的生理变化如月经恢复和（或）更年期症状的周期性波动时]

可以进行雌激素水平检测。绝经前乳腺癌患者

无论激素受体阳性或阴性

推荐在（新）辅助化疗前和化疗过程中使用OFS药物保护卵巢功能

降低卵巢功能早衰的发生风险

减少生育能力损害。推荐化疗前2周开始使用GnRHa

每28 d 1次

直至化疗结束后2周给予最后一剂药物。此外共识还建议

激素受体阳性乳腺癌患者抗肿瘤药物的临床试验

应尽可能纳入绝经前女性

在雌激素充分抑制的前提下

探索抗肿瘤药物对肿瘤生物学特性和患者长期生活质量的影响。

Abstract

Ovarian function suppression (OFS) has been used in the treatment of breast cancer for decades. Early adjuvant treatment studies have confirmed that the application of OFS alone can reduce the recurrence risk of breast cancer patients under the age of 50 and improve their survival. With the emergence of new evidence-based medical data

the Breast Cancer Professional Committee of the China Anti-Cancer Association convened domestic clinical experts in the field of breast cancer treatment

who jointly discussed and formulated the "Chinese Consensus of Ovarian Function Suppression in Early Breast Cancer (2021 edition) " on the basis of the 2018 edition. Consensus suggests that gonadotropin-releasing hormone agonist (GnRHa) should be the first choice of OFS for premenopausal hormone receptor-positive (HR positive) early breast cancer. Medium- and high-risk premenopausal HR positive breast cancer patients are recommended for endocrine therapy including OFS; low-risk patients are recommended for selective estrogen receptor modulator (SERM) monotherapy; premenopausal patients who use aromatase inhibitor (AI) instead of SERM need to receive OFS at the same time. For the medium- and high-risk patients with premenopausal HR positive early breast cancer

or the medium/high-risk patients analyzed by subpopulation treatment effect pattern plot (STEPP)

the combination of OFS and AI is recommended

and the combination of OFS and SERM is also an alternative choice. For patients with contraindications or at risk of contraindications to SERM

OFS combined with AI is recommended. The adjuvant endocrine therapy should be decided based on the status of ovarian function before adjuvant chemotherapy. If ovarian function protection is considered

GnRHa plus chemotherapy is recommended

which does not affect the survival benefits. If not

it is recommended that GnRHa can be used sequentially after chemotherapy. It is recommended that patients with confirmed ovarian function status after chemotherapy should not use GnRHa. The GnRHa adjuvant endocrine therapy should be used for 5 years. After 5 years

it is recommended to continue endocrine therapy combined with OFS for 5 years or 5 years of SERM therapy if the patients are still premenopausal and well tolerated. For low-risk patients who choose OFS instead of chemotherapy

OFS combined with endocrine therapy can be considered for 2 years. Full communication with patients based on adverse events of the OFS is needed before decision making. The sound management of adverse events will effectively relieve symptoms and increase the treatment compliance. For patients with OFS

it is not recommended to monitor estrogen levels routinely during the treatment and make decisions according to the test. However

when incomplete ovarian function suppression is suspected (including changes in usage such as unskilled injection

replacement of dosage forms

or indications of ovarian function recovery

such as menstrual recovery and/or the fluctuating perimenopausal symptoms)

estrogen testing can be performed. For premenopausal patients

no matter HRs are positive or negative

it is recommended to use ovarian function suppression drugs before and during (neo)adjuvant chemotherapy to protect ovarian function and reduce the risk of ovarian function failure and impaired fertility. It is recommended to start using GnRHa 2 weeks before chemotherapy

once every 28 days

until 2 weeks after the last dose of chemotherapy.In addition

the consensus suggests that premenopausal patients with sufficient OFS should be included in the clinical trials so as to investigate the impact of HR positive breast cancer drugs on tumor biological characteristics and long-term quality of life.

关键词

Keywords

references

曹毛毛 , 陈万青 . GLOBOCAN 2020全球癌症统计数据解读 [J ] . 中国医学前沿杂志(电子版) , 2021 , 13 ( 3 ): 63 - 69 .

CAO M M , CHEN W Q . Interpretation on the global cancer statistics of GLOBOCAN 2020 [J ] . Chin J Front Med Sci Electron Version , 2021 , 13 ( 3 ): 63 - 69 .

FAN L , STRASSER-WEIPPL K , LI J J , et al . Breast cancer in China [J ] . Lancet Oncol , 2014 , 15 ( 7 ): e279 - e289 .

EARLY BREAST CANCER TRIALISTS’ COLLABORATIVE GROUP(EBCTCG) . Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials [J ] . Lancet , 2005 , 365 ( 9472 ): 1687 - 1717 .

DAVIES C , PAN H C , GODWIN J , et al . Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial [J ] . Lancet , 2013 , 381 ( 9869 ): 805 - 816 .

GRAY R G , REA D , HANDLEY K , et al . aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6, 953 women with early breast cancer [J ] . J Clin Oncol , 2013 , 31 ( 18_suppl ): 5 .

LHRH-AGONISTS IN EARLY BREAST CANCER OVERVIEW GROUP , CUZICK J , AMBROISINE L , et al . Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials [J ] . Lancet , 2007 , 369 ( 9574 ): 1711 - 1723 .

FRANCIS P A , PAGANI O , FLEMING G F , et al . Tailoring adjuvant endocrine therapy for premenopausal breast cancer [J ] . N Engl J Med , 2018 , 379 ( 2 ): 122 - 137 .

NOH W C , LEE J W , NAM S J , et al . Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: the ASTRRA study [J ] . J Clin Oncol , 2018 , 36 ( 15_suppl ): 502 .

PERRONE F , DE LAURENTIIS M , DE PLACIDO S , et al . The HOBOE-2 multicenter randomized phase Ⅲ trial in premenopausal patients with hormone-receptor positive early breast cancer comparing triptorelin plus either tamoxifen or letrozole or letrozole + zoledronic acid [J ] . Ann Oncol , 2018 , 29 : viii704 .

HARRISON G S , WIERMAN M E , NETT T M , et al . Gonadotropin-releasing hormone and its receptor in normal and malignant cells [J ] . Endocr Relat Cancer , 2004 , 11 ( 4 ): 725 - 748 .

DOISNEAU-SIXOU S F , SERGIO C M , CARROLL J S , et al . Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells [J ] . Endocr Relat Cancer , 2003 , 10 ( 2 ): 179 - 186 .

TAN S H , WOLFF A C . Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer [J ] . Clin Breast Cancer , 2007 , 7 ( 6 ): 455 - 464 .

MCDONALD WADE S 3rd , HACKNEY M H , KHATCHERESSIAN J , et al . Ovarian suppression in the management of premenopausal breast cancer: methods and efficacy in adjuvant and metastatic settings [J ] . Oncology , 2008 , 75 ( 3/4 ): 192 - 202 .

中国抗癌协会乳腺癌专业委员会 . 中国抗癌协会乳腺癌诊治指南与规范(2021年版) [J ] . 中国癌症杂志 , 2021 , 31 ( 10 ): 954 - 1040 .

The Society of Breast Cancer China Anti-cancer Association . Guidelines for breast cancer diagnosis and treatment by China Anti-cancer Association (2021 edition) [J ] . China Oncol , 2021 , 31 ( 10 ): 954 - 1040 .

中国抗癌协会乳腺癌专业委员会 . 中国绝经前女性乳腺癌患者辅助治疗后绝经判断标准及芳香化酶抑制剂临床应用共识(草案修正案) [J ] . 中国癌症杂志 , 2011 , 21 ( 5 ): 418 - 420 .

The Society of Breast Cancer China Anti-cancer Association . Postmenopausal criteria for menopausal women and clinical consensus on aromatase application in China’s pre-menopausal women with breast cancer (draft amendment) [J ] . China Oncol , 2011 , 21 ( 5 ): 418 - 420 .

FRANCIS P A , REGAN M M , FLEMING G F , et al . Adjuvant ovarian suppression in premenopausal breast cancer [J ] . N Engl J Med , 2015 , 372 ( 5 ): 436 - 446 .

DEES E C , DAVIDSON N E . Ovarian ablation as adjuvant therapy for breast cancer [J ] . Semin Oncol , 2001 , 28 ( 4 ): 322 - 331 .

JONAT W , KAUFMANN M , SAUERBREI W , et al . Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex Early Breast Cancer Research Association Study [J ] . J Clin Oncol , 2002 , 20 ( 24 ): 4628 - 4635 .

BUI K T , WILLSON M L , GOEL S , et al . Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer [J ] . Cochrane Database Syst Rev , 2020 , 3 : CD013538 .

BURSTEIN H J , LACCHETTI C , ANDERSON H , et al . Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline update on ovarian suppression [J ] . J Clin Oncol , 2016 , 34 ( 14 ): 1689 - 1701 .

THOMSSEN C , BALIC M , HARBECK N , et al . St. Gallen/Vienna 2021: a brief summary of the consensus discussion on customizing therapies for women with early breast cancer [J ] . Breast Care (Basel) , 2021 , 16 ( 2 ): 135 - 143 .

PALUCH-SHIMON S , CARDOSO F , PARTRIDGE A H , et al . ESO-ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4) [J ] . Ann Oncol , 31 ( 6 ): 674 - 696 .

CARDOSO F , KYRIAKIDES S , OHNO S , et al . Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up [J ] . Ann Oncol , 2019 , 30 ( 8 ): 1194 - 1220 .

Lan B , Ma F , et al . Int J Cancer, 2018, 143:184;J Clin Oncol, 2007, 1;25(25):3837-3845; Ann Oncol , 2008 , 19 ( 8 ): 1423 - 1429 .

EARLY BREAST CANCER TRIALISTS’ COLLABORATIVE GROUP(EBCTCG) . Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials [J ] . Lancet , 2015 , 386 ( 10001 ): 1341 - 1352 .

REGAN M M , FRANCIS P A , PAGANI O , et al . Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT trials [J ] . J Clin Oncol , 2016 , 34 ( 19 ): 2221 - 2231 .

REGAN M M , FRANCIS P A , PAGANI O , et al . Absolute improvements in freedom from distant recurrence with adjuvant endocrine therapy for premenopausal women with HR + HER2 -negative breast cancer: results from TEXT and SOFT [J ] . J Clin Oncol , 2018 , 36 ( suppl 15 ): 503 - 503 .

LAMBERTINI M , BONI , MICHELOTTI A , et al . Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trial [J ] . JAMA , 2015 , 314 ( 24 ): 2632 - 2640 .

LAMBERTINI M , MOORE H C F , LEONARD R C F , et al . Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis of individual patient-level data [J ] . J Clin Oncol , 2018 , 36 ( 19 ): 1981 - 1990 .

PAN H C , GRAY R , BRAYBROOKE J , et al . 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years [J ] . N Engl J Med , 2017 , 377 ( 19 ): 1836 - 1846 .

NCCN Clinical Practice Guidelines in Oncology(NCCN Guidelines®) . Breast Cancer, Version 1 . 2022 [EB/OL ] . https://www.nccn.org/guidelines/guidelines-detail?category=1 & id=1419[2021 ] . https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419[2021]. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419[2021].

HICKEY M , SAUNDERS C , PARTRIDGE A , et al . Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer [J ] . Ann Oncol , 2008 , 19 ( 10 ): 1669 - 1680 .

LOIBL S , LINTERMANS A , DIEUDONNÉ A S , et al . Management of menopausal symptoms in breast cancer patients [J ] . Maturitas , 2011 , 68 ( 2 ): 148 - 154 .

PETREK J A , NAUGHTON M J , CASE L D , et al . Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study [J ] . J Clin Oncol , 2006 , 24 ( 7 ): 1045 - 1051 .

LIEM G S , MO F K , PANG E , et al . Chemotherapy-related amenorrhea and menopause in young Chinese breast cancer patients: analysis on incidence, risk factors and serum hormone profiles [J ] . PLoS One , 2015 , 10 ( 10 ): e0140842 .

SMITH I E , DOWSETT M , YAP Y S , et al . Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines [J ] . J Clin Oncol , 2006 , 24 ( 16 ): 2444 - 2447 .

宋三泰 , 陈建魁 , 单彬 . 规范乳腺癌性激素化验报告理顺应用AIs的绝经标准 [J ] . 中华乳腺病杂志(电子版) , 2012 , 6 ( 3 ): 238 - 243 .

SONG S T , CHEN J K , SHAN B . To standardize the sex hormone test report of breast cancer and straighten out the application of AIs’s menopausal standard [J ] . Chin J Breast Dis Electron Ed , 2012 , 6 ( 3 ): 238 - 243 .

江泽飞 , 王晓迪 . 乳腺癌内分泌治疗十个热点问题的思考 [J ] . 中华外科杂志 , 2015 , 2 ( 12 ): 895 - 900 .

JIANG Z F , WANG X D . Consideration and discussion on ten hot issues of endocrine therapy for breast cancer [J ] . Chin J Surg , 2015 , 2 ( 12 ): 895 - 900 .

GNANT M , MLINERITSCH B , STOEGER H , et al . Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial [J ] . Lancet Oncol , 2011 , 12 ( 7 ): 631 - 641 .

MOORE H C , UNGER J M , PHILLIPS K A , et al . Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy [J ] . N Engl J Med , 2015 , 372 ( 10 ): 923 - 932 .

MOORE H C F , UNGER J M , PHILLIPS K A , et al . Final analysis of the prevention of early menopause study (POEMS)/SWOG intergroup S0230 [J ] . J Natl Cancer Inst , 2019 , 111 ( 2 ): 210 - 213 .

DEL MASTRO L , BONI , MICHELOTTI A , et al . Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial [J ] . JAMA , 2011 , 306 ( 3 ): 269 - 276 .

LAMBERTINI M , BONI L C , MICHELOTTI A , et al . Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival [J ] . JAMA , 2015 , 314 ( 24 ): 2632 .

LAMBERTINI M , BONI L , MICHELOTTI A , et al . Final analysis of the PROMISE-GIM6 phase Ⅲ trial assessing GnRH agonist use during chemotherapy as a strategy to preserve ovarian function in premenopausal patients with early breast cancer [J ] . J Clin Oncol , 39 ( suppl 15 ): 516 - 516 .

PALUCH-SHIMON S , CARDOSO F , PARTRIDGE A H , et al . ESO-ESMO 4th international consensus guidelines for breast cancer in young women (BCY4) [J ] . Ann Oncol , 2020 , 31 ( 6 ): 674 - 696 .

CARDOSO F , KYRIAKIDES S , OHNO S , et al . Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up [J ] . Ann Oncol , 2019 , 30 ( 10 ): 1674 .

中国年轻乳腺癌诊疗与生育管理专家共识专家委员会 . 年轻乳腺癌诊疗与生育管理专家共识 [J ] . 中华肿瘤杂志 , 2019 , 41 ( 7 ): 486 - 495 .

Expert Committee on China’s Young Breast Cancer Diagnosis and Treatment and Fertility Management Expert Consensus . Expert consensus on diagnosis and treatment and birth management for young breast cancer [J ] . Chin J Oncol , 2019 , 41 ( 7 ): 486 - 495 .

Premenopausal women with breast cancer: developing drugs for treatment guidance for industry [P ] . FDA , 2020 , 2020-D-1553.

GAO J J , KROL D , NARAYAN P , et al . Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria [J ] . Ann Oncol , 2021 , 32 ( 8 ): 950 - 953 .

浏览量

9001

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

中国早期乳腺癌卵巢功能抑制临床应用专家共识（2024年版）

中国早期乳腺癌卵巢功能抑制临床应用专家共识(2016年版)

雌激素受体低表达早期乳腺癌的研究进展

关于女性乳腺癌患者绝经状态判断两个关键问题的临床思考

乳腺肿瘤整形与乳房重建专家共识（2022年版）